198205-95-7

Basic information

• Product Name: 2'-TRIFLUOROMETHYL-BIPHENYL-4-CARBALDEHYDE
• Synonyms: 4-[2-(TRIFLUOROMETHYL)PHENYL]BENZALDEHYDE;AKOS BAR-1774;2'-TRIFLUOROMETHYL-BIPHENYL-4-CARBALDEHYDE;2'-(TRIFLUOROMETHYL)[1,1'-BIPHENYL]-4-CARBALDEHYDE;2'-Trifluoromethyl-biphenyl-4-carbaldehyde
• CAS NO: 198205-95-7
• Molecular Formula: C₁₄H₉F₃O
• Molecular Weight: 250.22
• Product Categories: Biphenyl & Diphenyl ether
• Mol File: 198205-95-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 338.8 °C at 760 mmHg
• Flash Point: 163.3 °C
• Appearance: /
• Density: 1.251 g/cm³
• CAS DataBase Reference: 2'-TRIFLUOROMETHYL-BIPHENYL-4-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-TRIFLUOROMETHYL-BIPHENYL-4-CARBALDEHYDE(198205-95-7)
• EPA Substance Registry System: 2'-TRIFLUOROMETHYL-BIPHENYL-4-CARBALDEHYDE(198205-95-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Hazardous Substances Data: 198205-95-7(Hazardous Substances Data)

Usage

General Description

2'-Trifluoromethyl-biphenyl-4-carbaldehyde is a chemical compound categorized under the class of biphenyl and related compounds. Its molecular structure is characterized by the presence of two phenyl rings connected by a carbon-carbon single bond, with a trifluoromethyl group attached to one of the phenyl rings and a carbaldehyde, or formyl, group attached to the other. It's likely used in various chemical reactions and synthesis due to its specific configuration, and is possibly used in industrial applications, research, or production of complex molecules. Little data is available on potential hazards or safety information, implying it's not widely used or researched. Detailed examination is required to understand its physical and chemical properties, impact on human health or environment.

Upstream product

• 444-29-1 2-iodo(trifluoromethyl)benzene 
• 1122-91-4 4-bromo-benzaldehyde 
• 1423-27-4 2-(trifluoromethyl)phenylboronic acid 
• 392-83-6 o-trifluoromethylphenyl bromide 
• 87199-17-5 4-formylphenylboronic acid, 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 198205-79-7 2'-trifluoromethylbiphenyl-4-carboxylic acid 
• 198205-80-0 C₁₄H₁₁F₃O 
• 871250-39-4 (R,S)-2-cyclohexyl-1-(2'-trifluoromethylbiphenyl-4-yl)ethanol 

Relevant articles and documents

The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both in Vitro and in Vivo

The transient receptor potential melastatin 2 (TRPM2) channel is associated with ischemia/reperfusion injury, inflammation, cancer, and neurodegenerative diseases. However, the limit of specific inhibitors impedes the development of TRPM2-targeted therapeutic agents. To discover more potent and selective TRPM2 inhibitors, 59 N-(p-amylcinnamoyl) anthranilic acid (ACA) derivatives were synthesized and evaluated using calcium imaging and electrophysiology approaches. Systematic structure-activity relationship studies resulted in some potent compounds inhibiting the TRPM2 channel with sub-micromolar half-maximal inhibitory concentration values. Among them, the preferred compound A23 exhibited TRPM2 selectivity over TRPM8 and TRPV1 channels as well as phospholipase A2 and showed neuroprotective activity in vitro. Following pharmacokinetic studies, A23 was further evaluated in a transient middle cerebral artery occlusion model in vivo, which significantly reduced cerebral infarction. These data indicate that A23 might serve as a useful tool for TRPM2-related research as well as a lead compound for the development of therapeutic agents for ischemic injury.

Discovery and structure-activity relationships of pyrrolone antimalarials

In the pursuit of new antimalarial leads, a phenotypic screening of various commercially sourced compound libraries was undertaken by the World Health Organisation Programme for Research and Training in Tropical Diseases (WHO-TDR). We report here the detailed characterization of one of the hits from this process, TDR32750 (8a), which showed potent activity against Plasmodium falciparum K1 (EC50 ～ 9 nM), good selectivity (>2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways in which the molecule could be optimized. This compound represents an exciting start point for a drug discovery program for the development of a novel antimalarial.

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.